SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending as community members rally around this self-proclaimed 'chosen one' in the AI companionship space. The coin's connection to AI and a strong community are key talking points, with many expressing long-term bullish sentiment. Some users are pointing to the coin as the one to watch in the AI-driven meme coin sector.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel $INTC is trending amid speculation of a potential investment from Apple and closer collaboration between the two companies, fueling optimism about Intel's turnaround. Community members are discussing potential price targets and the impact of government support, while analysts debate the sustainability of the recent rally. Some investors believe that Intel's advanced packaging business is a key growth driver that is being overlooked.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending due to Jane Street's recent acquisition of a significant stake in the company, signaling strong institutional confidence. The community is speculating on the implications of this investment, with some suggesting a potential merger, strategic partnership, or gamma squeeze. Bullish investors are urging others to hold firm, anticipating further upward movement and a potential short squeeze.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending after positive Phase I/II data for its Huntington's disease treatment, showing a significant slowing of disease progression, although the treatment remains in early stages. The community is focused on a potential offering given the stock's surge, debating whether it's a buying opportunity or a chance to short, especially with analysts raising price targets. Discussions also involve the drug's potential market and approval timeline, with some comparing it to other biotech plays.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

IMRX is trending due to positive Phase 2a trial data for its pancreatic cancer treatment, showing a high survival rate. The community is discussing the potential for this to become a significant advancement in cancer treatment, although some are wary of potential dilution due to the company's financial situation and potential short selling.

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

TNF Pharmaceuticals Inc.

TNF Pharmaceuticals is trending due to its announced shift into quantum computing and rebranding, sparking significant community discussion. While some view this pivot and associated name change as a promising move into a high-growth sector, others express skepticism, citing the company's history and concerns about potential pump-and-dump schemes. The community is actively debating the company's prospects and the potential impact of its new technology on the cryptocurrency industry.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to excitement around its potential in the quantum computing sector, fueled by recent non-dilutive funding for key technology advancements. Community members are actively discussing the stock's momentum and debating its valuation, comparing it to other quantum computing stocks and even established tech companies. Some traders express optimism about long-term growth, while others caution against a potential pullback.

Stitch Fix, Inc. engages in the provision of personalized shipments of apparel, shoes, and accessories. Its main sections are men's, kids, petite, maternity, and plus apparels. The company was founded by Katrina Lake and Erin Morrison Flynn in February 2011 and is headquartered in San Francisco, CA.

Stitch Fix Inc - Ordinary Shares - Class A

Stitch Fix Inc

Stitch Fix is trending following its Q4 earnings report, with community discussions focusing on whether the company's turnaround strategy is gaining traction and its ability to achieve future growth.  Investors are weighing the positive aspects of the report against concerns about revenue guidance and declining active clients.  Overall sentiment appears divided as some view the recent activity as a potential fade while others anticipate further gains.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz is trending as investors discuss its recent offering of exchangeable senior notes and a settlement distribution. Community members are debating the implications of the new debt versus the cash influx, with some eyeing a potential rally due to high short interest. Broader conversations include Hertz's leveraged position regarding interest rates and its ongoing recovery from bankruptcy.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as traders discuss its potential to catch up with the recent gains of other Chinese tech stocks like BABA and BIDU, with some highlighting its attractive valuation and strong logistics network. Community members are actively debating potential catalysts, technical indicators, and optimal entry points, while also closely monitoring option activity and potential price targets. Despite some frustration with recent performance, there is a general sentiment of bullishness and anticipation for a breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter spiked around Invivyd on Monday after the company said its monoclonal antibodies pemivibart and VYD2311 continued to neutralize the emerging XFG variant of COVID-19 in laboratory tests.The company reported that both antibodies remained effective against XFG, which U.S. Centers for Disease Control and Prevention data and wastewater surveillance suggest is driving a rising wave of infections in the U.S.&nbsp;Similar results were shown against other circulating variants, including NB.1.8.1, LF.7.9 and LP.8.1. Invivyd said it identified no resistant strains.The data will be submitted to the U.S. Food and Drug Administration (FDA) for planned inclusion in the fact sheet for pemivibart, which is currently authorized under emergency use for pre-exposure prevention of COVID-19 in certain immunocompromised patients.The update follows news last week that Invivyd reached alignment with the FDA on a streamlined regulatory pathway for VYD2311.&nbsp;In a recent Type C meeting, the agency advised that a single Phase 2/3 randomized, placebo-controlled trial with a relatively modest number of symptomatic COVID-19 cases could support a biologics license application.&nbsp;Invivyd said it plans to test two doses of VYD2311 and has clinical supply on hand.Infections are growing or likely growing in 34 states, with wastewater data showing high or very high viral levels in 12 states, the company said, citing CDC forecasts.&nbsp;Invivyd said the structural target of its antibodies has remained stable across major variants since Omicron BA.2, supporting continued neutralization activity.On Stocktwits, retail sentiment for Invivyd was ‘bullish’ amid a 175% surge in 24-hour message volume.One user noted they had seen Invivyd fall to $0.48 before quickly rebounding above $1, adding that good timing was the only way to make money with the stock.&nbsp;<stembedurl>https://stocktwits.com/Jack696/message/625670790</stembedurl>Another user said they had added to their position at $0.61.<stembedurl>https://stocktwits.com/alexx013/message/625643913</stembedurl><a href="https://stocktwits.com/symbol/IVVD">Invivyd’s stock</a> has risen 31% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Invivyd’s (IVVD) stock has risen 31% so far in 2025. (Photo credit: Getty Images)

Retail Chatter Surges Around Invivyd After Data Show Pemgarda Neutralizes XFG COVID-19 Variant

The company also recently aligned with the FDA on a streamlined path to potential approval for its next-generation antibody VYD2311.

Equity

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -200.00% and -23.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of +17.95% and +57.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of +33.33% and +177.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Retail buzz around Invivyd Inc. spiked on Monday after it revealed its launch of a discovery program to create a measles-specific monoclonal antibody.&nbsp;Healthcare providers managing measles patients and outbreak situations contacted Invivyd to explore access to its prospective medicine since no approved treatments or post-exposure prophylaxis options exist for measles.Invivyd shares surged 29.7% on Monday to close at $0.84.Currently, clinicians lack numerous treatment options for managing measles cases.&nbsp;Children who have contracted measles receive high-dose Vitamin A to aid their recovery process, especially when their bodies lack Vitamin A.&nbsp;While high-dose Vitamin A therapy helps treat measles in children who have a deficiency of the vitamin, it shows potential liver toxicity and remains underutilized.&nbsp;Human donor-derived pooled plasma immune globulin (IVIG) is a mix of different antibodies from several donors that hasn't been officially approved, and its inconsistent makeup makes it less reliable for widespread use.Measles vaccines stand as the best protective measure available, yet their effectiveness diminishes because some populations fail to access or refuse them, leaving unprotected gaps after exposure to the virus.&nbsp;The latest research indicates that diseases like measles, which were previously under control, could reemerge and lead to serious outcomes such as pneumonia, encephalitis,&nbsp; and long-lasting immunological consequences.The monoclonal antibody discovery program of Invivyd would grow its portfolio, which presently contains next-generation treatments for COVID-19, respiratory syncytial virus (RSV), and influenza.&nbsp;Retail sentiment around Invivyd turned ‘extremely bullish’, with a 4,800% spike in 24-hour message volume.&nbsp;Some users expressed confidence that the stock could reach multiple dollars, while others pointed to monoclonal antibodies as the “future of medicine.”<stembedurl>https://stocktwits.com/trader2sde/message/614373951</stembedurl><stembedurl>https://stocktwits.com/TheFnFortune/message/614327973</stembedurl>The stock has risen 74.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’

Invivyd unveiled a discovery program for a measles-targeted monoclonal antibody, responding to provider demand amid a lack of approved treatments or post-exposure options. 

These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

This Penny Stock Just Doubled on Clinical Trial Results. Analysts Think It Can Surge 266% From Here.

Investors could consider this penny stock after its COVID-19 antibody breakthrough sent shares soaring, and analysts see massive triple-digit gains ahead.

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (OtherTLPPF) and Invivyd (IVVD)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Telix Pharmaceuticals Ltd. (TLPPF Research Report) and Invivyd...

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Invivyd Inc

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Stocktwits

Costco Wholesale Corp

) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Current Price	$1.22
Prev Close	$1.16
Open	$1.16
Dividend Yield	0.00%
50-Day Moving Average	$0.8898
Beta	1.34
Avg. Volume	12.39M
PE Ratio	-1.26

52-Week High	$2.74
52-Week Low	$0.3546
Market Capitalization	$226.15M
EPS (Annual)	-$1.43
Price to Book	3.26
Revenue Per Employee	$256,404.04
Enterprise Value/EBITDA	N/A

IVVD
Invivyd Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IVVD News

IVVD Invivyd Inc